Vaccines against Covid-19: Two ethical dilemmas to consider
Article Sidebar
Published:
Jan 4, 2021
Keywords:
vaccine development, human challenge trials, ethical distribution, SARS-CoV-2
Main Article Content
Abstract
The Covid-19 epidemic has altered and redefined the capacity of health systems around the globe, while being a challenge for bioethicists who must focus on issues such as the ethical process of vaccine development, and the strategies to be followed, to ensure fair and equitable distribution of these vaccines. Human challenge trials and their ethical implications are discussed, as a possible way to accelerate the availability of vaccines against Covid-19. Another ethical problem that is discussed is the global dilemma that will have to be faced to ensure a universal and accessible vaccine. Some viable strategies for the distribution of vaccines, both worldwide and at the local level are presented. Different philosophical viewpoints are presented regarding both problems, offering diverse arguments and answers to the ethical dilemmas exposed.
Downloads
Download data is not yet available.
PLUMX Metrics
Article Details
How to Cite
Zonenzsain Laiter, Y. (2021). Vaccines against Covid-19: Two ethical dilemmas to consider. Medicina Y Ética, 32(1), 215–231. https://doi.org/10.36105/mye.2021v32n1.06
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Medicina y Ética is distributed under a Creative Commons License Atribución-NoComercial-CompartirIgual 4.0 Internacional.
The author keeps the property rights with no restriction whatsoever and guarantees the magazine the right to be the first publication of the work. The author is free to deposit the published version in any other medium, such as an institutional archive or on his own website.
References
1. Corum Jonathan, Grady Denise, Wee Sui-Ly, Zimmer Carl. Coronavirus Vaccine
Tracker. 2020. [Consultado el 18 de agosto de 2020]. Recuperado en: https://
www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
2. Spinney L. When will a coronavirus vaccine be ready? The Guardian. 2020; 04-
06. T08:55:36.000Z.
3. Pandey SC, Pande V, Sati D, Upreti S, Samant M. Vaccination strategies to
combat novel coronavirus SARS-CoV-2. Life sciences (1973). 1° de septiembre
de 2020; 256: 117956. https://doi.org/10.1016/j.lfs.2020.117956
4. Georgina Casey. A vaccine for Covid-19? Nursing New Zealand (Wellington,
N.Z: 1995). 1° de junio de 2020; 26(5): 29.
5. ISRCTN. ISRCTN89951424: A phase III study to investigate a vaccine against Covid-
19. [Consultado el 18 de agosto de 2020]. Recuperado en: http://www.isrctn.
com/ISRCTN89951424
6. Roestenberg M, Mo A, Kremsner PG, Yazdanbakhsh M. Controlled human infections:
A report from the controlled human infection models workshop, Leiden
University Medical Centre 4-6, May 2016. Vaccine. 2017; 35(51): 7070-7076.
https://doi.org/10.1016/j.vaccine.2017.10.092
7. Mateus B. Human challenge trials are being pushed to develop a vaccine
against the coronavirus. [Consultado el 20 de agosto de 2020]. Recuperado en:
https://www.wsws.org/en/articles/2020/05/05/vacc-m05.html
8. Sketcher B. Guidelines. West Auckland, New Zealand. Beth Sketcher; 2018.
9. Grethlein J, Huitink L, Tagliabue A. Introduction. 2020.
10. Richards AD. Ethical guidelines for deliberately infecting volunteers with Covid-
19. Journal of medical ethics. Agosto de 2020; 46(8): 502-504.
https://doi.org/10.11 36/medethics-2020-106322
11. Singer P. The Case for Human Covid-19. Challenge Trials by Peter Singer &
Isaac Martínez. 2020. [Consultado del 18 de agosto de 2020]. Recuperado en:
https://www.project-syndicate.org/commentary/ethics-of-human-covid19-challenge-
trials-by-peter-singer-and-isaac-martinez-1-2020-08
12. Meagher KM, Cummins NW, Bharucha AE, Badley AD, Chlan LL, Wright RS.
Covid-19 Ethics and Research. Mayo Clinic Proceedings. Junio de 2020; 95(6):
1119-1123. https://doi.org/10.1016/j.mayocp.2020.04.019
13. Verity R, Okell LC, Dorigatti I. Estimates of the severity of coronavirus disease
2019: a model-based analysis (2020). 1° de abril de 2020; vol 20; 669.
14. Eyal N, Lipsitch M, Smith PG. Human challenge studies to accelerate coronavirus
vaccine licensure. Marzo de 2020.
15. Walker P, Whittaker C, Watson O, Baguelin M, Ainslie K, Bhatia S, et al. Report
12: The global impact of Covid-19 and strategies for mitigation and suppression.
2020.
16. Why scientists hope to inject some people with Zika virus. [Consultado del 19
de agosto de 2020]. Recuperado en: https://www.npr.org/sections/health-shots/
2016/02/25/468120804/why-scientists-hope-to-inject-some-people-with-zika-virus
17. Mullard A. Covid-19 vaccine development pipeline gears up. The Lancet (British
edition). 6 de junio de 2020; 395(10239): 1751-1752. https://doi.org/10.1016/s0140-
6736(20) 31252-6
18. Commitment and call to action: Global collaboration to accelerate new Covid-
19 health technologies. [Consultado el 25 de agosto de 2020]. Recuperado en:
https://www.who.int/news-room/detail/24-04-2020-commitment-and-call-to-actionglobal-
collaboration-to-accelerate-new-Covid-19-health-technologies
19. Bollyky TJ, Gostin LO, Hamburg MA. The equitable distribution of Covid-19
therapeutics and vaccines. JAMA: The Journal of the American Medical Association.
7 de mayo de 2020; 323(24): 2462. https://doi.org/10.1001/jama.2020.6641
20. Vacuna contra Covid-19. Ya hay invitación de Rusia a México para participar
en vacuna «Sputnik V». 2020. [Consultado el 7 de septiembre de 2020]. Recuperado
en: https://www.eluniversal.com.mx/na cion/vacuna-contra-Covid-19-ya-hayinvitacion-
de-rusia-mexico-para-participar-en-vacuna-sputnik-v. https://doi.org/10.24215/166965 81e471
21. Liu Y, Salwi S, Drolet BC. Multivalue ethical framework for fair global allocation
of a Covid-19 vaccine. Journal of Medical Ethics. Agosto de 2020; 46(8): 499-501.
https://doi.org/10.1136/medethics-2020-106516
22. Gavi, the Vaccine Alliance. [Consultado el 12 de agosto de 2020]. Recuperado
en: https://www.gavi.org/
23. 172 countries & multiple candidate vaccines engaged in Covid-19 vaccine global
access facility. [Consultado el 25 de agosto de 2020]. Recuperado en: https://
cepi.net/news_cepi/172-countries-multiple-candidate-vaccines-engaged-in-Covid-
19-vaccine-global-access-facility/. https://doi.org/10.1021/cen-09819-buscon4
24. Up to 100 million Covid-19 vaccine doses to be made available for low, and
middle-income countries as early as 2021. [Consultado el 25 de agosto de 2020].
Recuperado en: https://www.gavi.org/news/media-room/100-million-Covid-19-vaccine-
doses-available-low-and-middle-income-countries-2021. https://doi.org/10.
1136/bmj. m3857
25. AFP, Redacción, Ciudad de México y Buenos Aires, Uno TV y Fundación Carlos
Slim acuerdan con AstraZeneca producción de vacuna contra Covid-19 para
América Latina. 2020. [Consultado el 7 de septiembre de 2020]. Recuperado en:
https://www.unotv.com/nacional/astrazeneca-y-fundacion-carlos-slim-produciranvacuna-
contra-covid-19-para-america-latina/ https://doi.org/10.18235/0002587
26. Malm H, May T, Francis LP, Omer SB, Salmon DA, Hood R. Ethics, pandemics,
and the duty to treat. The American Journal of Bioethics. 23 de septiembre de
2008; 8(8): 4-19. https://doi.org/10.1080/15265160802317974
27. Parfit D. Another defence of the priority view. Utilitas. Septiembre de 2012;
24(3): 399-440. https://doi.org/10.1017/s095382081200009x
28. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair
allocation of scarce medical resources in the time of Covid-19. N Engl J Med.
2020; 382(21): 2049-2055. https://doi.org/10.1056/nejmsb2005114
29. Giubilini A, Savulescu J, Wilkinson D. Covid-19 Vaccine: Vaccinate the young
to protect the old? Journal of Law and the Biosciences. 26 de junio de 2020.
https://doi. org/10.1093/jlb/lsaa050
Tracker. 2020. [Consultado el 18 de agosto de 2020]. Recuperado en: https://
www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
2. Spinney L. When will a coronavirus vaccine be ready? The Guardian. 2020; 04-
06. T08:55:36.000Z.
3. Pandey SC, Pande V, Sati D, Upreti S, Samant M. Vaccination strategies to
combat novel coronavirus SARS-CoV-2. Life sciences (1973). 1° de septiembre
de 2020; 256: 117956. https://doi.org/10.1016/j.lfs.2020.117956
4. Georgina Casey. A vaccine for Covid-19? Nursing New Zealand (Wellington,
N.Z: 1995). 1° de junio de 2020; 26(5): 29.
5. ISRCTN. ISRCTN89951424: A phase III study to investigate a vaccine against Covid-
19. [Consultado el 18 de agosto de 2020]. Recuperado en: http://www.isrctn.
com/ISRCTN89951424
6. Roestenberg M, Mo A, Kremsner PG, Yazdanbakhsh M. Controlled human infections:
A report from the controlled human infection models workshop, Leiden
University Medical Centre 4-6, May 2016. Vaccine. 2017; 35(51): 7070-7076.
https://doi.org/10.1016/j.vaccine.2017.10.092
7. Mateus B. Human challenge trials are being pushed to develop a vaccine
against the coronavirus. [Consultado el 20 de agosto de 2020]. Recuperado en:
https://www.wsws.org/en/articles/2020/05/05/vacc-m05.html
8. Sketcher B. Guidelines. West Auckland, New Zealand. Beth Sketcher; 2018.
9. Grethlein J, Huitink L, Tagliabue A. Introduction. 2020.
10. Richards AD. Ethical guidelines for deliberately infecting volunteers with Covid-
19. Journal of medical ethics. Agosto de 2020; 46(8): 502-504.
https://doi.org/10.11 36/medethics-2020-106322
11. Singer P. The Case for Human Covid-19. Challenge Trials by Peter Singer &
Isaac Martínez. 2020. [Consultado del 18 de agosto de 2020]. Recuperado en:
https://www.project-syndicate.org/commentary/ethics-of-human-covid19-challenge-
trials-by-peter-singer-and-isaac-martinez-1-2020-08
12. Meagher KM, Cummins NW, Bharucha AE, Badley AD, Chlan LL, Wright RS.
Covid-19 Ethics and Research. Mayo Clinic Proceedings. Junio de 2020; 95(6):
1119-1123. https://doi.org/10.1016/j.mayocp.2020.04.019
13. Verity R, Okell LC, Dorigatti I. Estimates of the severity of coronavirus disease
2019: a model-based analysis (2020). 1° de abril de 2020; vol 20; 669.
14. Eyal N, Lipsitch M, Smith PG. Human challenge studies to accelerate coronavirus
vaccine licensure. Marzo de 2020.
15. Walker P, Whittaker C, Watson O, Baguelin M, Ainslie K, Bhatia S, et al. Report
12: The global impact of Covid-19 and strategies for mitigation and suppression.
2020.
16. Why scientists hope to inject some people with Zika virus. [Consultado del 19
de agosto de 2020]. Recuperado en: https://www.npr.org/sections/health-shots/
2016/02/25/468120804/why-scientists-hope-to-inject-some-people-with-zika-virus
17. Mullard A. Covid-19 vaccine development pipeline gears up. The Lancet (British
edition). 6 de junio de 2020; 395(10239): 1751-1752. https://doi.org/10.1016/s0140-
6736(20) 31252-6
18. Commitment and call to action: Global collaboration to accelerate new Covid-
19 health technologies. [Consultado el 25 de agosto de 2020]. Recuperado en:
https://www.who.int/news-room/detail/24-04-2020-commitment-and-call-to-actionglobal-
collaboration-to-accelerate-new-Covid-19-health-technologies
19. Bollyky TJ, Gostin LO, Hamburg MA. The equitable distribution of Covid-19
therapeutics and vaccines. JAMA: The Journal of the American Medical Association.
7 de mayo de 2020; 323(24): 2462. https://doi.org/10.1001/jama.2020.6641
20. Vacuna contra Covid-19. Ya hay invitación de Rusia a México para participar
en vacuna «Sputnik V». 2020. [Consultado el 7 de septiembre de 2020]. Recuperado
en: https://www.eluniversal.com.mx/na cion/vacuna-contra-Covid-19-ya-hayinvitacion-
de-rusia-mexico-para-participar-en-vacuna-sputnik-v. https://doi.org/10.24215/166965 81e471
21. Liu Y, Salwi S, Drolet BC. Multivalue ethical framework for fair global allocation
of a Covid-19 vaccine. Journal of Medical Ethics. Agosto de 2020; 46(8): 499-501.
https://doi.org/10.1136/medethics-2020-106516
22. Gavi, the Vaccine Alliance. [Consultado el 12 de agosto de 2020]. Recuperado
en: https://www.gavi.org/
23. 172 countries & multiple candidate vaccines engaged in Covid-19 vaccine global
access facility. [Consultado el 25 de agosto de 2020]. Recuperado en: https://
cepi.net/news_cepi/172-countries-multiple-candidate-vaccines-engaged-in-Covid-
19-vaccine-global-access-facility/. https://doi.org/10.1021/cen-09819-buscon4
24. Up to 100 million Covid-19 vaccine doses to be made available for low, and
middle-income countries as early as 2021. [Consultado el 25 de agosto de 2020].
Recuperado en: https://www.gavi.org/news/media-room/100-million-Covid-19-vaccine-
doses-available-low-and-middle-income-countries-2021. https://doi.org/10.
1136/bmj. m3857
25. AFP, Redacción, Ciudad de México y Buenos Aires, Uno TV y Fundación Carlos
Slim acuerdan con AstraZeneca producción de vacuna contra Covid-19 para
América Latina. 2020. [Consultado el 7 de septiembre de 2020]. Recuperado en:
https://www.unotv.com/nacional/astrazeneca-y-fundacion-carlos-slim-produciranvacuna-
contra-covid-19-para-america-latina/ https://doi.org/10.18235/0002587
26. Malm H, May T, Francis LP, Omer SB, Salmon DA, Hood R. Ethics, pandemics,
and the duty to treat. The American Journal of Bioethics. 23 de septiembre de
2008; 8(8): 4-19. https://doi.org/10.1080/15265160802317974
27. Parfit D. Another defence of the priority view. Utilitas. Septiembre de 2012;
24(3): 399-440. https://doi.org/10.1017/s095382081200009x
28. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair
allocation of scarce medical resources in the time of Covid-19. N Engl J Med.
2020; 382(21): 2049-2055. https://doi.org/10.1056/nejmsb2005114
29. Giubilini A, Savulescu J, Wilkinson D. Covid-19 Vaccine: Vaccinate the young
to protect the old? Journal of Law and the Biosciences. 26 de junio de 2020.
https://doi. org/10.1093/jlb/lsaa050